The startup will use the funds to support a pivotal clinical study designed to obtain US Food and Drug Administration clearance for its iNOS sepsis test.
The funding will support the creation of biorepositories, biomarker discovery and validation, and personalized cancer therapeutic clinical trials.
The NCI and NIA will provide support for research into the mammalian target of rapamycin signaling network, which may play an important role in healthy aging.
Scientists from the company and JHU will use a $340,000 NCI grant to test metabolomic pathways as indicators of lung cancer therapeutic resistance.
The Early Career Development Award will fund studies into gene expression controls in corn and aims to engage students in all aspects of lab research.
Three grant types will support clinical, basic, and applied research using genomic and pharmacogenomic approaches, among others.
The small grants will fund biomarker studies, molecular science, and diagnostic research into immunodeficiency diseases.
A new grant program aims to encourage the combination of quantitative and physical science with biomedicine to develop biomarkers and other new technologies.
The research may use genomic, proteomic, and other methods to understand the molecular reasons why some foods inhibit or suppress cancer.
The research program will fund technology development and implementation grants that use new stem cell technologies to understand genetic variation and disease.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.